+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb



Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb



International Surgery 82(2): 170-174



The relationship between the expression of p53 and p21 in cases of advanced gastric cancer (t3) with lymph node metastasis [n1(+) or n2 (+)] and the long-term effects of continuous hyperthermic peritoneal perfusion (CHPP) immediately after resection was evaluated. Between 1983 and 1989, 74 patients with gastric cancer [t3, n1(+) or n2(+)] underwent curative gastrectomy and survived without postoperative complications. These patients were followed up for at least six years. Thirty-seven patients died from recurrence of cancer. In 34 patients who had tumors designated p53-/p21+ or p53+/p21+, CHPP reduced the percentage of patients who died from recurrence of cancer from 10/20 (50%) to 3/14 (21.4%, P = 0.184). However, in 40 patients who had tumors designated p53-/p21- or p53+/p21-, the percentage of patients who were treated with or without CHPP and died from recurrence of cancer was the same, 6/10 (60%) and 18/30 (60%). In the case of patients who had p21-positive tumors, the 5-year survival rate of 11 patients who were treated with CHPP (72.7%) was higher than that of 17 patients who were not treated with CHPP (41.2%, p = 0.027). However, in the case of patients with p21-negative tumors, the 5-year survival rate of 10 patients who were treated with CHPP (50%) was not very different from that of 28 patients who were not treated with CHPP (42.9%, p = 0.308). These results indicate that the CHPP might be effective in preventing the recurrence of cancer in patients with p21-positive regardless of the expression of p53.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047222998

Download citation: RISBibTeXText

PMID: 9331847


Related references

Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. Journal of Surgical Oncology 2018, 2018

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. Cancer 98(1): 128-134, 2003

Prognostic significance of CD44 and nm23 expression in patients with stage II and stage IIIA gastric carcinoma. Journal of Surgical Oncology 71(1): 22-28, 1999

Long-term survival after pharmacosensitivity-directed adjuvant four-drug chemotherapy in stage II node-positive and stage IIIA breast cancer patients. International Journal of Oncology 7(SUPPL ): 960, 1995

Sequential chemotherapy and radiotherapy for initial management of Stage IIIA and Stage IIIB non-small cell lung cancer induction chemotherapy. Lung Cancer 7(1-2): 77-84, 1991

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology 25(30): 4736-4742, 2007

Rational Integration of Radiation and Chemotherapy in Patients with Unresectable Stage IIIA or IIIB NSCLC. Chest Journal 103(1): 35s-42s, 1993

Neoadjuvant chemotherapy and chemoradiotherapy in locally advanced stage IIIA and IIIB of non-small-cell bronchial carcinoma (the Essen concept). Praxis 86(42): 1647-1653, 1998

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (<pCR) after primary chemotherapy. Oncologist 14(11): 1051-1060, 2010

Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer. Clinical Lung Cancer 10(5): 353-359, 2010

Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients. Journal of Thoracic Oncology 2(4): 293-298, 2007

Five-year survival of stage IIIA-IIIB (non-N3) non-small cell lung cancer patients after platinum/gemcitabine induction chemotherapy and surgery. Journal of ChemoTherapy 22(3): 191-196, 2010

Chemotherapy versus chemotherapy plus radiotherapy for stage IIIA, IIIB Hodgkin's disease. A southwest oncology group study. International Journal of Radiation Oncology*biology*physics 5(Supp-S2): 138-0, 1979

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clinical Cancer Research 10(12 Pt 2): 4215s-4219s, 2004

Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. Journal of Clinical Oncology 24(27): 4397-4404, 2006